Canada's Profound Medical Q4 revenue up 43% but misses estimates

Profound Medical

05/03/2026 21:23

Overview

Canada medical device firm's Q4 revenue grew 43% yr/yr but missed analyst expectations

Q4 net loss widened to $8.2 mln from $4.9 mln yr ago

Company expanded TULSA-PRO system and strategic partnerships globally

Outlook

Profound expects TULSA-PRO installs to reach about 120 by end of 2026

Company anticipates high double-digit to low triple-digit revenue growth

Profound aims to triple market size to 600,000 patients annually with TULSA-AI

Result Drivers

TULSA-PRO SALES - Q4 revenue growth driven by increased sales of TULSA-PRO systems and expanding sales pipeline

GLOBAL PARTNERSHIPS - Expansion of strategic partnerships and distribution agreements in Canada, Saudi Arabia, Australia, and New Zealand

Company press release: ID:nGNX3Mct2l

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$6 mln
$7.23 mln (3 Analysts)
Q4 EPS
-$0.27
Q4 Net Income
-$8.2 mln
Q4 Operating Expenses
$11.4 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)